Skip to main content
Scientific publications

At Day One, we use the power of leading-edge science to improve patient outcomes.

We believe timely and transparent dissemination of data from our clinical trials and other studies is essential to inform clinical decision making and to advance scientific understanding. Our comprehensive list of publications is below.
May 2023
pLGG disease burden and healthcare utilization: linked claims and EHR data study
Tabitha Cooney, Sandie Yu, Shailaja Daral, Blake Krebs, Riddhi Markan, Michelle A Field, Mark Kieran, Sandya Govinda Raju, Susan Zelt
2023 ASPHO Conference: Poster 258
April 2023
Clinical activity of the type II pan-RAF inhibitor tovorafenib in BRAF-fusion melanoma
Jeeyun Lee, MD, Natraj R. Ammakkanavar, MD, Aprajita Saini, MS, Mark W. Kieran MD, PhD, Lisa M. Kopp, DO, MPH, Bert H. O’Neil, MD
19th EADO Congress 2023: Paper #174
November 2022
FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors
Kilburn L, Landi D, Leary S, Ziegler DS, Baxter P, Franson A, McCowage G, Waanders AJ, Van der Lugt J, Oren MY, Gerber NU, Gottardo NG, Khuong-Quang D-A, Nysom K, Bailey S, Hernáiz Driever S, Perreault S, Witt O, Hahn S, Hargrave D, Hassall T, Jabado N,Kang HJ, Larouche V, Toledano H, Kline C, Abdelbaki MS, Chi SN, Gardner SL, Whipple N, Mueller S, Blackman, SC, Zhao X, Da Costa D, Cox MC, Packer R, Hansford JR 2022 Society for Neuro-Oncology - Annual Meeting
2022 SNO Annual Meeting: Abstract CTNI-68
November 2022
LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric patients with newly diagnosed low-grade glioma harboring an activating RAF alteration
van Tilburg CM, Jones DTW, Schmidt R, Avula S, Schouten-van Meeteren A, Sehested A Opocher E, Hernáiz Driever P, Witt R, Ziegler DS, Blackman SC, Zhao X,Tsao L-P,Manley P,Cox MC, Hargrave D, Witt O 2022 Society for Neuro-Oncology - Annual Meeting
2022 SNO Annual Meeting: Abstract CTNI-30
June 2022
FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors
Landi D, Ziegler DS, Franson AT, Baxter PA, Leary SES, Larouche V, Waanders AJ, van der Lugt J, McCowage G, Jabado N, Cornelio I, Blackman SC, Da Costa D, Cox MC, Witt O, Kilburn L, Hansford JR.
ASCO Annual Meeting 2022: Abstract TPS10062
November 2021
Activity of pan-RAF inhibitor DAY101 in a pediatric patient with a recurrent spindle cell sarcoma harboring a novel SNX8-BRAF gene fusion
Offer K, McGuire M, Venetsanakos E, Blackman S, Song K, Goldfischer M, Cox M
2021 Connective Tissue Oncology Society Annual Meeting